Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/11/20
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020GlobeNewsWire • 11/04/20
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021GlobeNewsWire • 10/19/20
Are More Positive Results on the Way for Kamada’s COVID-19 Pneumonia Treatment?24/7 Wall Street • 09/08/20
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)GlobeNewsWire • 09/08/20
What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President TrumpThe Motley Fool • 08/25/20
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary ObjectiveGlobeNewsWire • 08/19/20
Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/12/20
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position GlobeNewsWire • 08/12/20
Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in IsraelGlobeNewsWire • 08/10/20
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020GlobeNewsWire • 08/05/20